Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
نویسندگان
چکیده
Hiltrud Brauch and Werner Schroth, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; and University Tübingen, Tübingen, Germany Matthew P. Goetz, Mayo Clinic, Rochester, MN Thomas E. Mürdter and Stefan Winter, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; and University Tübingen, Tübingen, Germany James N. Ingle, Mayo Clinic, Rochester, MN Matthias Schwab, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; University Tübingen; and Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital Tübingen, Tübingen, Germany Michel Eichelbaum, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; and University Tübingen, Tübingen, Germany
منابع مشابه
Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling
PURPOSE To overcome cytochrome P450 2D6 (CYP2D6) mediated tamoxifen resistance in postmenopausal early breast cancer, CYP2D6 phenotype-adjusted tamoxifen dosing in patients with impaired CYP2D6 metabolism and/or the application of endoxifen, the most potent tamoxifen metabolite, are alternative treatment options. To elucidate both strategies comprehensively we used a physiologically-based pharm...
متن کاملCYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
BACKGROUND Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy. In this study, we investigated the clinical relevance of CYP2D6 polymorphisms. METHODS We obtained tumor tissues and iso...
متن کاملCYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study
INTRODUCTION AND AIMS Tamoxifen is an adjuvant drug effective in treating hormone receptor - positive breast cancer. However, 30%-50% of patients relapse and many develop adverse effects, such as hot flashes and fatty liver. Allelic variations altering the activity of cytochrome P450-2D6 enzyme affect response to tamoxifen by modulating metabolism of tamoxifen into its pharmacologically active ...
متن کاملNo association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
BACKGROUND CYP2D6 is considered the key enzyme in tamoxifen metabolism. Several studies have investigated the relationship between the CYP2D6 genotype and tamoxifen treatment outcome, with discrepant results. CYP2D6 inhibitor use, aromatase inhibitor use, and chemotherapy may account for some of the discrepancies. We examined the association between CYP2D6 genotype and early breast cancer event...
متن کاملPharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
BACKGROUND Tamoxifen is metabolically activated via a CYP2D6 enzyme system to the more potent hydroxylated derivatives 4-hydroxytamoxifen and endoxifen. This study addresses the pharmacological importance of endoxifen by simulating clinical scenarios in vitro. METHODS Clinical levels of tamoxifen metabolites in postmenopausal breast cancer patients previously genotyped for CYP2D6 were used in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
دوره 31 2 شماره
صفحات -
تاریخ انتشار 2013